Literature DB >> 18351300

Most pancreatic cancer resections are R1 resections.

Irene Esposito1, Jörg Kleeff, Frank Bergmann, Caroline Reiser, Esther Herpel, Helmut Friess, Peter Schirmacher, Markus W Büchler.   

Abstract

BACKGROUND: Curative resection has been shown to be one of the key factors influencing survival of pancreatic ductal adenocarcinoma (PDAC) patients. Although general guidelines for the processing of pancreatic specimens have been established, there is currently no widely accepted standardized protocol for pathological examination, especially with respect to resection margins.
METHODS: Here we present a single-center experience with 111 consecutive macroscopic complete pancreatic head resections for PDAC carried out between 2005 and 2006 by using standardized pathological processing and reporting. The pancreatic transection margin, as well as the bile duct and stomach/duodenum margins and the circumferential soft tissue margins (medial, anterior surface, superior, and posterior), were inked and analyzed. R1 was defined as a distance of the tumor from the resection margin of < or = 1 mm.
RESULTS: One hundred eighty-eight consecutive macroscopic complete pancreatic head resections carried out for PDAC without a standardized protocol between 2002 and 2004 were used as a control group. The R1 rate for resections carried out with the standardized protocol was 76%. The medial (68%) and the posterior (47%) margins were most commonly involved, and in 32% of the cases, more than one margin was affected. The R1 resection rate in the period without standardized pathological reporting was 14%.
CONCLUSIONS: This study highlights the importance of pathological reporting and suggests that tumor growth patterns and thorough examination but not surgical technique determine R1 resection rates in PDAC.

Entities:  

Mesh:

Year:  2008        PMID: 18351300     DOI: 10.1245/s10434-008-9839-8

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  179 in total

Review 1.  Pathologic assessment of gastrointestinal tract and pancreatic carcinoma after neoadjuvant therapy.

Authors:  Reetesh K Pai; Rish K Pai
Journal:  Mod Pathol       Date:  2017-08-04       Impact factor: 7.842

2.  How to counter the problem of R1 resection in duodenopancreatectomy for pancreatic cancer?

Authors:  Eliane Angst; Corina Kim-Fuchs; Yojena Chittazhathu Kurian Kuruvilla; Daniel Inderbitzin; Matteo Montani; Daniel Candinas; Beat Gloor
Journal:  J Gastrointest Surg       Date:  2012-01-10       Impact factor: 3.452

3.  Uncinate process first--a novel approach for pancreatic head resection.

Authors:  Thilo Hackert; Jens Werner; Jürgen Weitz; Jan Schmidt; Markus W Büchler
Journal:  Langenbecks Arch Surg       Date:  2010-06-27       Impact factor: 3.445

Review 4.  [Pathology and classification of intraductal papillary mucinous neoplasms of the pancreas].

Authors:  A M Schlitter; I Esposito
Journal:  Chirurg       Date:  2012-02       Impact factor: 0.955

5.  Three-Dimensional Fixation: Pathological Protocol Following Pancreaticoduodenectomy with Portal Vein Resection for Pancreatic Cancer.

Authors:  Masayuki Tanaka; Yosuke Inoue; Kiyoshi Matsueda; Makiko Hiratsuka; Mariko Muto; Shoji Kawakatsu; Yoshihiro Ono; Yoshihiro Mise; Takeaki Ishizawa; Hiromichi Ito; Yu Takahashi; Yutaka Takazawa; Akio Saiura
Journal:  J Gastrointest Surg       Date:  2019-04-01       Impact factor: 3.452

Review 6.  Retroperitoneal margin of the pancreaticoduodenectomy specimen: anatomic mapping for the surgical pathologist.

Authors:  Mahmoud A Khalifa; Vlad Maksymov; Corwyn Rowsell
Journal:  Virchows Arch       Date:  2008-12-06       Impact factor: 4.064

7.  En bloc vascular resection for the treatment of borderline resectable pancreatic head carcinoma.

Authors:  Hirohisa Kitagawa; Hidehiro Tajima; Hisatoshi Nakagawara; Isamu Makino; Tomoharu Miyashita; Masatoshi Shoji; Shinichi Nakanuma; Norihiro Hayashi; Hiroyuki Takamura; Tetsuo Ohta; Hiroshi Ohtake
Journal:  Mol Clin Oncol       Date:  2014-02-27

8.  Novel toll-like receptor 2 ligands for targeted pancreatic cancer imaging and immunotherapy.

Authors:  Amanda Shanks Huynh; Woo Jin Chung; Hyun-Il Cho; Valerie E Moberg; Esteban Celis; David L Morse; Josef Vagner
Journal:  J Med Chem       Date:  2012-11-08       Impact factor: 7.446

9.  Redefining the R1 resection for pancreatic ductal adenocarcinoma: tumour lymph nodal burden and lymph node ratio are the only prognostic factors associated with survival.

Authors:  Biku J John; Prashant Naik; Alastair Ironside; Brian R Davidson; Guiseppe Fusai; Roopinder Gillmore; Jennifer Watkins; Sakhawat H Rahman
Journal:  HPB (Oxford)       Date:  2013-01-14       Impact factor: 3.647

10.  Pancreaticoduodenectomy following chemoradiotherapy for locally advanced adenocarcinoma of the pancreatic head.

Authors:  Quentin Denost; Christophe Laurent; Jean-Philippe Adam; Maylis Capdepont; Veronique Vendrely; Denis Collet; Antonio Sa Cunha
Journal:  HPB (Oxford)       Date:  2013-01-10       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.